Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
Haïk
S
S
Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l'Hôpital, 75651 Paris Cedex 13, France. haik@chups.jussieu.fr
Brandel
J P
JP
Salomon
D
D
Sazdovitch
V
V
Delasnerie-Lauprêtre
N
N
Laplanche
J L
JL
Faucheux
B A
BA
Soubrié
C
C
Boher
E
E
Belorgey
C
C
Hauw
J J
JJ
Alpérovitch
A
A
D001921:Brain / Q000473:pathology; D007562:Creutzfeldt-Jakob Syndrome / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D004341:Drug Evaluation; D006801:Humans; D011796:Quinacrine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D017211:Treatment Failure
D011796:Quinacrine